Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) had an increase of 0.49% in short interest. ZEAL’s SI was 185,000 shares in May as released by FINRA. Its up 0.49% from 184,100 shares previously. With 19,000 avg volume, 10 days are for Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL)’s short sellers to cover ZEAL’s short positions. The SI to Zealand Pharma A/S – American Depositary Shares’s float is 0.8%. The stock increased 1.41% or $0.22 during the last trading session, reaching $15.82. About 2,455 shares traded. Zealand Pharma A/S (NASDAQ:ZEAL) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics medicines in Denmark. The company has market cap of $470.01 million. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. It currently has negative earnings. The firm markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
More recent Zealand Pharma A/S (NASDAQ:ZEAL) news were published by: Streetinsider.com which released: “Zealand Pharma (ZEAL) Reports Successful End-of-Phase 2 Meeting with FDA on Glepaglutide for Short Bowel …” on April 26, 2018. Also Benzinga.com published the news titled: “32 Stocks Moving In Tuesday’s Mid-Day Session” on April 24, 2018. Benzinga.com‘s news article titled: “28 Stocks Moving In Tuesday’s Pre-Market Session” with publication date: April 24, 2018 was also an interesting one.
Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.79 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 150.3 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.
Investors sentiment decreased to 1.34 in Q4 2017. Its down 0.28, from 1.62 in 2017Q3. It dropped, as 53 investors sold Vertex Pharmaceuticals Incorporated shares while 160 reduced holdings. 72 funds opened positions while 213 raised stakes. 232.48 million shares or 0.46% more from 231.42 million shares in 2017Q3 were reported. Webster Comml Bank N A holds 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 28 shares. Hillsdale Investment stated it has 2,920 shares or 0.07% of all its holdings. Hudson Bay Mgmt Lp owns 50,000 shares. Macquarie Grp Inc Limited reported 168,273 shares. Btg Pactual Glob Asset Mgmt Ltd accumulated 0.25% or 4,543 shares. Grandfield & Dodd Limited Liability Com reported 6,248 shares stake. Millennium Limited Liability Corp holds 0.25% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 1.23 million shares. Public Employees Retirement System Of Ohio holds 195,535 shares. Amer Registered Investment Advisor has 2,835 shares for 0.2% of their portfolio. Amalgamated Bankshares holds 33,269 shares. Raymond James Tru Na has 0.04% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Twin Tree Management Limited Partnership holds 50,154 shares or 0.06% of its portfolio. 725,000 are held by Healthcor Management Lp. The Maryland-based Rock Springs Mngmt L P has invested 1.16% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Mngmt reported 0.01% stake.
Vertex Pharmaceuticals Inc Ma EVP – Global Research and CSO David Altshuler on the 16/05/2018 unloaded a total of 98 shares of the ‘s company worth total $15,266 US Dollars. This is at an average price-per-share of $155.8 US Dollars. David Altshuler owns 0.03% of the -company’s market cap or 69,999 shares.
More recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Streetinsider.com which released: “Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies – RBC” on May 15, 2018. Also Seekingalpha.com published the news titled: “Vertex Pharmaceuticals Heads Toward An Important Tipping Point” on May 01, 2018. Fool.com‘s news article titled: “Vertex Pharmaceuticals Takes a Detour Around the FDA’s Roadblock” with publication date: April 30, 2018 was also an interesting one.
Since December 11, 2017, it had 0 buys, and 45 sales for $106.34 million activity. $17.67 million worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by LEIDEN JEFFREY M. $15,266 worth of stock was sold by ALTSHULER DAVID on Tuesday, May 15. $334,232 worth of stock was sold by SMITH IAN F on Tuesday, January 16. Another trade for 5,122 shares valued at $772,493 was made by Chodakewitz Jeffrey on Monday, February 12. $600,680 worth of stock was sold by Parini Michael on Thursday, February 1. On Monday, February 26 the insider Arbuckle Stuart A sold $1.09 million. Another trade for 2,155 shares valued at $366,350 was sold by Sachdev Amit.
The stock increased 0.40% or $0.62 during the last trading session, reaching $156.16. About 971,857 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 76.59% since May 17, 2017 and is uptrending. It has outperformed by 65.04% the S&P500.
Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals has $212.0 highest and $85.0 lowest target. $180.63’s average target is 15.67% above currents $156.16 stock price. Vertex Pharmaceuticals had 102 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Jefferies with “Buy” on Wednesday, January 31. As per Monday, September 25, the company rating was maintained by BMO Capital Markets. The company was maintained on Thursday, February 1 by Leerink Swann. The stock has “Outperform” rating by BMO Capital Markets on Wednesday, March 29. As per Thursday, July 27, the company rating was maintained by Oppenheimer. The company was maintained on Tuesday, February 13 by JMP Securities. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by BMO Capital Markets on Thursday, February 1. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Cowen & Co on Monday, September 25. The rating was upgraded by H.C. Wainwright on Friday, October 30 to “Buy”. On Tuesday, March 13 the stock rating was maintained by Cowen & Co with “Buy”.